1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Veterinary Oncology Market By Animal Type By Therapy By Cancer Type By Region, Industry Analysis and Forecast, 2020 - 2026

Global Veterinary Oncology Market By Animal Type By Therapy By Cancer Type By Region, Industry Analysis and Forecast, 2020 - 2026

  • April 2020
  • 209 pages
  • ID: 5893267
  • Format: PDF
  • KBV Research


Table of Contents

The Global Veterinary oncology Market size is expected to reach $369.2 Million by 2026, rising at a market growth of 13.2% CAGR during the forecast period. Cancer is one of the main causes of morbidity in veterinary patients and one of the most important surgical procedures undertaken by veterinarians is the surgical removal of tumors. The annual physical examination plays a crucial role in the diagnosis of neoplasia, either specifically through palpation or through paraneoplastic syndromes that can be detected on regular blood and urine analysis. The physical examination allows for the diagnosis of the involvement of cancers and the identification of concurrent conditions that can affect the treatment plan.

When a tumor is identified, the vet records its size, location, and gross appearance, and palpate regional lymph nodes. The suspicion of a metastatic neoplasm rises as the lymph nodes are swollen, solid, or immovable; however, normal lymph node palpation does not guarantee a lack of metastasis. Hence in most cases, some form of biopsy of the lymph node is recommended.

Intralesional, or debulking, surgery is incomplete resection of a tumor (within the pseudo capsule) with the residual gross disease. It is rarely an appropriate cure for neoplastic diseases, be it benign or malignant. This procedure leaves a tumor cell strain that is often too large, even with adjunctive therapies, such as radiation therapy and chemotherapy, to achieve a successful outcome.

Cancer is prevalent in dogs and in recent years, chemotherapy has progressed dramatically with canine oncology becoming a practice in many countries like the UK, Australia, and the US. However, there were no large-scale trials of the potential side effects of chemotherapeutic drugs in associated animals and very little debate on the ethics of using chemotherapy in these species. In general, the prognosis for animals suffering from malignant neoplasia (which can be conducive to chemotherapy) remains low, and the role of oncology in veterinary medicine can be debated.

Based on Animal Type, the market is segmented into Canine and Feline. Based on Therapy, the market is segmented into Chemotherapy, Radiology, Surgery, Immunotherapy and Others. Based on Cancer Type, the market is segmented into Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer and Others. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Inc., Regeneus Ltd., Elanco Animal Health, Inc., Zoetis, Inc., Varian Medical Systems, Inc., PetCure Oncology, LLC (Accelitech, LLC), AB Science SA, Rhizen Pharmaceuticals S.A., and Nippon Zenyaku Kogyo Co., Ltd.

Strategies deployed in Veterinary Oncology Market

Nov-2019: Varian Medical Systems came into partnership with VCA Animal Hospitals. The partnership was announced as a part of the company’s newly launched network of VCA Pet CancerCare Centers across North America for providing advanced pet cancer radiotherapy treatment at its specialty hospitals.

Aug-2019: Elanco Animal Health Inc. signed an agreement to acquire Bayer AG’s animal-health unit. The acquisition would strengthen Elanco’s Animal Health business.

Aug-2019: Boehringer Ingelheim signed partnership agreement with The University of Texas MD Anderson Cancer Center. The partnership was focused on conducting collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers.

Jul-2019: Boehringer Ingelheim took over AMAL Therapeutics, a biotechnology company focused on cancer immunotherapy. The acquisition helped the company to become an innovator of novel cancer therapies, including immuno-oncology treatments.

Jul-2019: Elanco Animal Health completed the acquisition of Aratana Therapeutics. The acquisition complemented Elanco’s field presence and capitalized on new opportunities for Elanco pet therapy brands.

Jun-2019: Varian acquired Endocare and Alicon. The acquisition broadened its portfolio of multidisciplinary integrated cancer care solutions.

Jun-2018: Zoetis teamed up with Regeneron Pharmaceuticals. Through this collaboration, the companies aimed to research the use of Regeneron’s monoclonal antibody therapeutics in animals and discover new veterinary treatments.

Jul-2017: PetCure Oncology collaborated with Varian Medical Systems. The collaboration was aimed at bringing a different level of care to pets suffering from cancer. Under this collaboration, the Varian’s software suite, including the RapidPlan and ARIA platforms were integrated across PetCure Oncology’s national network of veterinary cancer care centers.

May-2017: Karyopharm Therapeutics signed a licensing agreement with Anivive Lifesciences, a biotech company focused on innovations in the veterinary drug and bioinformatics space. Following this agreement, the latter company got the exclusive rights from Karyopharm to research, develop, and commercialize verdinexor (KPT-335) for the treatment of cancer in companion animals.

May-2017: Varian Medical Systems launched the Halcyon system, a new device for cancer treatment. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT). This new treatment system has been designed for expanding the availability of high-quality cancer care and help save the lives of millions more cancer patients

Scope of the Study

Market Segmentation:

By Animal Type

• Canine and

• Feline

By Therapy

• Chemotherapy

• Radiology

• Surgery

• Immunotherapy and

• Others

By Cancer Type

• Lymphoma

• Mast Cell Cancer

• Mammary & Squamous Cell Cancer and

• Others

By Geography

• North America

o US

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific


o Brazil

o Argentina


o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

• Boehringer Ingelheim International GmbH

• Karyopharm Therapeutics, Inc.

• Regeneus Ltd.

• Elanco Animal Health, Inc.

• Zoetis, Inc.

• Varian Medical Systems, Inc.

• PetCure Oncology, LLC (Accelitech, LLC)

• AB Science SA

• Rhizen Pharmaceuticals S.A.

• Nippon Zenyaku Kogyo Co., Ltd.

Unique Offerings

• Exhaustive coverage

• Highest number of market tables and figures

• Subscription based model available

• Guaranteed best price

• Assured post sales research support with 10% customization free

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Rhabdomyosarcoma Global Clinical Trials Review, H1, 2020

  • $ 2500
  • May 2020
  • 246 pages

Rhabdomyosarcoma Global Clinical Trials Review, H1, 2020 Summary This clinical trial report, “Rhabdomyosarcoma Global Clinical Trials Review, H1, 2020" provides an overview of Rhabdomyosarcoma Clinical ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on